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Background: Bilirubin circulates throughout the 
human cardiovascular system.  Its interaction with 
the vascular wall is not well known.  
Results: Bilirubin alters Raf/ERK/MAPK 
pathway, cellular YY1 location and calcium-
dependent YY1proteolysis in human vascular 
cells.    
Conclusion: At high physiological levels 
bilirubin, inhibits cell growth, proliferation, and 
does not cause apoptosis. 
Significance: The observations provide 
opportunities for prevention and treatment of 
cardiovascular diseases. 
 
SUMMARY 
The biological effects of bilirubin, still poorly 
understood, are concentration-dependent 
ranging from cell protection to toxicity. Here 
we present data that at high nontoxic 
physiological concentrations bilirubin inhibits 
growth of proliferating human coronary artery 
smooth muscle cells by three events. It impairs 
the activation of Raf/ERK/MAPK pathway and 
the cellular Raf and cyclin D1 content that 
results in retinoblastoma protein hypo-
phosphorylation on amino acids Ser608 and 
Ser780. These events impede the release of YY1 
to the nuclei and its availability to regulate the 
expression of genes and to support cellular 
proliferation. Moreover, altered calcium influx 
and calpain II protease activation leads to 
proteolytical degradation of transcription 
factor YY1. We conclude that in the serum 
stimulated  human vascular smooth muscle 
primary cell cultures (hVSMC) bilirubin favors 
growth arrest and we propose that this activity 
is regulated by its interaction with the 
Raf/ERK/MAPK pathway, effect on cyclin D1 
and Raf content, altered Rb profile of hypo-
phosphorylation, calcium influx, and YY1 
proteolysis. We propose that these activities 
together culminate in diminished 5S and 45S 
ribosomal RNA synthesis and cell growth 
arrest. The observations provide important 
mechanistic insight into the molecular 
mechanisms underlying the transition of 
human vascular smooth muscle cells from 
proliferative to contractile phenotype and the 
role of bilirubin in this transition.  
 
 
INTRODUCTION  
Early studies established that mitochondria might 
be a major target of bilirubin, leading to 
uncoupling of oxidative phosphorylation (1). 
Other studies indicate that bilirubin could inhibit 
DNA and protein synthesis in some tissues as well 
as cell lanes, and induce apoptosis (2, 3). 
Apart from its toxic effect at high concentrations, 
bilirubin also seems to play an important role in 
protecting cells from oxidative damage by acting 
as a scavenger of peroxyl-, hydroperoxyl- and 
hydroxyl radicals (4). The extended system of 
conjugated bilirubin double bonds and the 
presence of a reactive hydrogen atom underlie its 
functions as a powerful biological chain-breaking 
antioxidant supporting the idea of a beneficial role 
(4). Indeed, recent clinical data associates the 
increased total serum bilirubin level with lessened 
susceptibility to peripheral arterial disease (PAD) 
(5) and coronary artery disease (CAD) (6). 
Moreover, there is also accumulating evidence 
from epidemiological studies showing that 
individuals with high normal plasma bilirubin 
levels, including individuals with Gilbert 
syndrome, have a lesser incidence of CAD and 
carotid vascular plaque formation (7). Thus, there 
is considerable clinical evidence that elevated 
serum bilirubin level  is associated with a 
diminished susceptibility to atherosclerotic 
vascular disease. Studies in rats demonstrate a 
salutary bilirubin effect through its suppression of 
vascular neointimal formation in the carotid artery 
due to impaired activation of MAPKs. 
Involvements of transcription factor YY1 and the 
retinoblastoma protein (Rb) in rodents have also  
been proposed. However, an exact molecular 
mechanism of bilirubin action on human VSMC 
remains to be established.  
         Thus we set out to investigate the 
mechanisms underlying bilirubin action in primary 
cell cultures of human coronary artery smooth 
muscle cells. By treating growth stimulated 
primary cell culture with physiologically relevant 
concentrations of bilirubin in a complex with FBS 
we were able to detect an effect of bilirubin on the 
Raf/MEK/ERK pathway. We report for specific 
effect on cyclin D1 content and the Rb profile of 
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 3 
amino acids phosphorylation. Altered influx of 
calcium, resulting in calpain II protease circuit 
activation occurs as well. This culminates in 
protein cleavage of the transcription factor YY1 
by calpain II. Furthermore, we observed 
alterations in the YY1 regulated expression of 5S 
ribosomal RNA (5S rRNA) and 45S rRNA. 
Together with the proteoliticaly lowered YY1 
levels, altered Raf/MEK/ERK pathway, cyclin D1 
content, and Rb profile of hypophosphorylation, 
we suggest that this could explain the growth 
arrest effect of bilirubin on hVSMC. These 
observations provide new insights into the 
molecular mechanisms and pathways underlying 
the switch of hVSMC from proliferative to 
contractile phenotype and the role of bilirubin in 
this transition. These novel observations may 
provide opportunities for prevention and treatment 
of cardiovascular diseases by laying the ground for 
the development of novel therapeutic strategies 
that target these pathways. 
 
EXPERIMENTAL PROCEDURES 
 
Cell culture, treatment, immunofluorescence. 
hCASMC from different donors, a female 
Caucasian 46 years, a male Caucasian 21 years 
and a male Caucasian 49 years, from Cambrex, 
USA, were cultivated in SmGM-2 (Cambrex, 
USA) at 37°C in a humidified atmosphere of 5% 
CO2. All experiments were performed at passages 
5 to 8 of the cells under continuous subconfluent 
conditions. For bilirubin treatment cells were 
cultivated up to 70% confluence. Cells were first 
starved for 12 hours in medium with 0.5% fetal 
bovine serum (FBS) and for another 24 hours in 
the absence of FBS. After starvation, cells were 
cultivated in medium with 10% FBS and with or 
without 100 µM bilirubin. The bilirubin stock 
solution was prepared in 20 µM NaOH and 10 
mg/ml BSA. Cells were harvested for RNA and 
protein after 0 hours (starved cells), 8, 16 and 24 
hours upon cultivation with or without bilirubin. In 
some experiments 0.5mM EGTA-AM (Molecular 
Probes) or 1mM EGTA were added to the cell 
medium 20 min prior harvesting. The intracellular 
Ca content was compared by treating the cells with 
100 nM of fura red for 20 min as recommended by 
the supplier (Molecular Probes). Fluorescent 
microscopy (Zeiss Axiovert 135 fluorescence 
microscope) images of fura red fluorescence at 
514 nm exitation, 550-nm emission were collected 
ant the staining intensity was measured in pixels 
with ImageJ software (NIH, USA) and Adobe 
PhotoShop. Cell culture without bilirubin served 
as a negative control. Measurements were 
performed in triplicates. Cells were prepared for 
immunofluorescent microscopy as previously 
described (12). 
 
Isolation of RNA and RT-qPCR. Total RNA is 
isolated from the cells with the RNeasy Mini kit 
from (QIAGEN) as recommended by the 
manufacturer. For RT–qPCR experiments, 600 ng 
total RNA was reverse transcribed using a cDNA 
Synthesis kit (Invitrogen) with random-oligo 
primers. For cellular qRT–PCR, 500 ng total RNA 
was reverse transcribed using the same conditions 
as above; 1/10 dilutions were used in triplicates 
with 0.2 µM gene specific primers and 5 µl 
LightCycler 480 SYBR Green I Master kit 
(Stratagene) in 20 µl reactions. Gene specific 
primers were selected (PRIMER BLAST, NIH), 
synthesized and gel purified. The sequences of the 
primers are: 5SRNA- CCT CCA GTG GTT GTC 
GAC TT  (forward) and GAA CGA CAC ACC 
ACC GTT C  (reverse); 45SRNA- CCT CCA 
GTG GTT GTC GAC TT  (forward) and GAA 
CGA CAC ACC ACC GTT C  (reverse); β-actin:
 AAC TGG AAC GGT GAA GGT GAC 
AGC  (forward), TGG CTT TTA GGA TGG CAA 
GGG ACT  (reverse); α-smooth muscle actin:
 AAT GAG ATG GCC ACT GCC GC  
(forward), CAG AGT ATT TGC GCT CCG GA  
(reverse). The relative level of gene expression 
was normalized to the β-actin gene.   
3H-thymidine incorporation, apoptosis, and cell 
cycle analyses. For thymidine incorporation 
hCASMC were cultivated in 24-well plates. 1 µCi 
of [methyl-3H] thymidine (Perkin Elmer) was 
added per well to measure de novo DNA synthesis 
by determining level of cellular [3H] thymidine 
incorporation. 
The results of the individual treatments were 
obtained in duplicates using a scintillation counter 
(Beckmann). FITC-labeled annexin V 
(PromoKine) was used to identify early apoptotic 
cells following the protocol of the supplier. The 
number of the annexin V positive cells was 
counted by fluorescence microscopy in four 
independent experiments. Cell cycle analysis was 
performed as previously reported (8). DNA 
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 4 
content analysis of samples was performed in 
duplicates using a FACS scan (Becton Dickinson) 
and analyzed with Cellquest software (Becton 
Dickinson). 
Protein isolation and western blots. Total cell 
lysates were prepared by resuspending the cells in 
RIPA buffer (Boston Bioproducts) supplemented 
with 1mM EDTA. Nuclear and cytosolic extracts 
were prepared with the NE-PER kit (Thermo 
Scientific) following the manufacturer’s protocol. 
The protein concentration of the extracts was 
determined using the DC Protein Assay (Bio-Rad) 
according to the manufacturer’s protocol with a 
BSA standard curve. Routinely 40 µg of protein 
per lane was used for western blot with mouse 
anti-YY1 antibody (Santa Cruz), chicken 
polyclonal anti-YY1 antibody (Cell Code, MA), 
anti-Sp1 antibody (Santa Cruz), the antibodies to 
total Rb, hypophosphorylated Rb (D20), phospho 
Rb (Ser 608), phospho Rb (Ser 612), pPhospho Rb 
(Ser 780), ERK (p42/44 MAPK), Phospho ERK 
(Tyr 202/204), MEK, phospho MEK (Ser 
217/221), mTOR, cyclin D1 were purchased from 
Cell Signaling Tech, Danvers.  
 The immunoreactive bands were visualized with 
the Supersignal West Femto Kit (Pierce). The 
scanned x-ray films were then analyzed with 
ImageJ software (NIH, USA) and Adobe 
PhotoShop.  
Data analysis and statistical methods. The 
comparative CT method (Applied Biosystem) was 
used to analyze the data resulting from the RT-
qPCR experiments. Student's t test for unpaired 
results was performed to evaluate differences 
between two groups. Differences were considered 
to be significant for values of p < 0.05. All figures 
are assembled in FreeHand and Adobe PhotoShop. 
 
RESULTS 
 
Bilirubin induces growth arrest in proliferating 
hVSMC. Vascular smooth muscle cell 
proliferation is known to be the key event in 
vascular response to injury. We examined the 
impact of bilirubin on cultured primary hVSMC 
from the coronary artery. Cellular proliferation 
was measured with the 3H-thymidine incorporation 
assay. Cells cultivated with increasing 
concentrations of bilirubin exhibited lower 
thymidine incorporation (Figure 1 A, lanes 3-5), in 
a dose dependent manner, than cells cultivated 
without bilirubin (lane 2). The lowest thymidine 
incorporation was observed in FBS starved cells 
(lane 1).  
To assess if cellular apoptosis contributes to the 
observed low rate of thymidine incorporation, we 
performed an annexin V apoptosis assay. The 
results indicate that the same amounts of cells 
were undergoing apoptosis when cultivated in the 
presence or absence of bilirubin (B, lane 1). Tested 
bilirubin concentrations up to 100 µM did not 
exhibit a significant increase in apoptosis. Less 
than 13% of the cells were stained positively for 
annexin V. In the positive control, significantly 
more cells were positively stained for annexin V in 
response to the apoptosis-inducing treatment with 
TNFα and IL-1β. 
To further investigate the mechanism of the 
underlying bilirubin-induced inhibitory effect on 
cell proliferation, cell cycle analysis was 
performed with propidium iodine (PI) DNA 
staining and subsequent FACS analysis (C). The 
assay illustrated that the majority (>70%) of the 
cells that were cultured for 24 hours in complete 
medium, FBS, and 100 µM bilirubin were growth 
arrested at the G0/G1 phase of the cell cycle In the 
absence of bilirubin, however, significantly fewer 
cells (<60 %) were found in the G0/G1 phase. In 
serum starved cells, over 80% of the cells were 
found in the G0/G1 compartment of the cell cycle. 
Thus, the sole mechanism by which bilirubin 
inhibits hVSMC proliferation is likely to be 
through growth arrest in the G0/G1 phase of the 
cell cycle. More importantly, the anti-proliferative 
effect is not due to cell death. 
 
Bilirubin alters Rb phosphorylation pattern, 
cellular YY1 distribution and binding with Rb. 
It is known that cell cycle transition from G0/G1 
to S phase is controlled by Rb phosphorylation (9). 
At least 16 different Rb amino acids are known to 
be differentially phosphorylated, that leads to 
altered Rb-protein transcription factors 
interactions and regulatory functions in gene 
transcription (10, 11). Therefore, we investigated 
if bilirubin would change the amino acids 
phosphorylation profile of the cellular Rb. We 
performed Western blot experiments of total cell 
lysates from bilirubin treated and untreated cells, 
with antibodies that recognize individual phospho-
Rb variants (Fig. 2). We observed 
hypophosphorylation of Rb at SER780 (panel A) 
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 5 
and SER608 in cells cultivated in the presence of 
FBS and 100 µM bilirubin compared to cells 
cultivated in sole FBS-supplemented medium. 
These changes are consistent throughout 8, 16 and 
24 hours of bilirubin treatment. The 
hypophosphorylation pattern for SER608 and 
SER780 resembles the serum-starved cells (lane 
1). In contrary, the level of the phospho-
SER612variant  does not change significantly in 
response to bilirubin. Hence the variant serves as 
an internal control for equal protein loading.  
The hypophosphorylated Rb binds YY1 and holds 
the protein in the cytosol (12).  It is not known if 
the Rb hypophosphorylation on SER608 and 
SER780 in bilirubin treated cells will be sufficient 
to bind and prevent the YY1 migration to the 
nuclei. We verified the Rb-YY1 binding and 
cellular localization by immunofluorescence and 
antibodies to Rb (S612) and YY1.  Following 
treatment with FBS together with bilirubin (panel 
B) most of the cells stained positively for the 
YY1-Rb complex in the cytosol (orange). In 
contrast, YY1 stained green in the nuclei of cells 
that received only FBS. In our second assay for the 
YY1-hypophosphorylated Rb binding in bilirubin 
treated VSMC we tested the ability of antibody to 
YY1 to capture the hypophosphorylated Rb (panel 
C). Consistent with the immunofluorescence 
results (panel B), YY1-specific antibody captured 
∼35% of the hypophosphorylated Rb (lane 2) in 
the cytosolic extract from 16 hours bilirubin 
treated cells (lane 1). Pre-immune mouse antibody 
served as a negative control (lane 3).  
Our experiments argue that treatment with 100µM 
bilirubin in serum stimulated hVSMC leads to 
hypophosphorylation of Rb at SER608 and 
SER780. The phosphorylation level at position 
Ser612 however, remains high and is seemingly 
independent of the treatment.  Importantly, the 
hypophosphorylated Rb variant in the bilirubin 
treated cells is active to bind YY1 impeding the 
release to the nuclei.  
 
Bilirubin has an effect on the  Raf/ERK/MAPK 
pathway. The Raf/MEK/ERK kinase pathway is a 
major pathway that has been shown to influence 
Rb phosphorylation as well as cell cycle 
transitions. We assayed if this pathway is 
influenced by hVSMCs treatment with bilirubin. 
Western blot experiments were performed with 
cell lysates from bilirubin treated and untreated 
cells using antibodies that are specific to various 
total- and phospho-forms of the kinases Raf, 
MEK-1/2, and ERK-1/2 proteins (Fig. 3). We 
observed that, while total protein levels were 
constant, MEK-1/2, and ERK-1/2  were less 
phosphorylated 8 hours after bilirubin treatment 
when compared to bilirubin untreated cells (Fig. 3, 
lanes 2-3). The inhibitory effect of bilirubin on 
phosphorylation was most pronounced in ERK 1/2 
throughout the tested 24 hours (Fig. 3, lanes 1-7). 
Bilirubin also showed an inhibitory effect on the 
cellular cyclin D1 level through the tested 24 
hours. In addition, less total Raf protein was 
detectable in the 24 hours bilirubin fraction (lanes 
6). The protein level of β-actin seems not to be 
altered by bilirubin treatment remaining nearly 
similar to the levels in the growth-arrested control 
cells before serum stimulation (Fig. 3, lanes 2-7). 
This protein serves as a control for equal protein 
loading.  
The data argue for a specific inhibitory effect of 
bilirubin on Raf (Ser338), MEK (Ser217/221), and 
ERK (Thr202/Tyr204) phosphorylation. In 
addition, bilirubin treated hVSMC have 
significantly less cyclin D1 protein, as well as Raf. 
The observed changes coincide with  the 
bilirubin–specific profile of Rb 
hypophosphorylation (10) (Fig. 2) and cellular 
growth arrest (Fig. 1).  
 
Bilirubin exposure increases Ca2+-influx and 
activation of calpain II that manifests in 
proteolytical YY1 cleavage. Previously we 
reported that YY1 is a direct Rb target in VSMC 
(12). Hypophosphorylated Rb is known to restrain 
YY1 in the cytosol, preventing its migration into 
the nucleus to regulate genes that are directly 
involved in the hVSMC transition from growth 
arrest to the S phase (12). In western blot 
experiments we compared the nuclear YY1 
content in nuclear extracts from cell cultures after 
serum stimulation for 8 hours and 24 hours in the 
presence or absence of bilirubin (Fig. 4, A). The 
results consistently revealed presence of >2 times 
less immunologically reactive full length YY1 in 
bilirubin treated cells (lanes 3 and 5) when 
compared to the serum stimulated control cells 
(lanes 2 and 4).   
The low YY1 protein content could reflect an 
altered YY1mRNA content in response to 
bilirubin treatment. Accordingly, we measured the 
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 6 
YY1 mRNA content by RT-qPCR in bilirubin 
treated and untreated cells. The YY1 mRNA 
content was found to remain relatively constant 
(panel B). Thus, the bilirubin-related alteration in 
YY1 protein content is likely to be post-
translationaly regulated. To assay for degradation 
of the protein upon bilirubin treatment we 
performed Western blots with polyclonal anti-
YY1 antibodies (panel c) and total cell extract. 
The blots indicate the presence of faster migrating 
YY1 ~35 kDa fragments (13) in the bilirubin cell 
culture lysates suggesting for an intracellular 
proteolysis of YY1 (C, lane 1). The cleavage is 
YY1-specific since two other assayed Zn-finger 
transcription factors, Sp1 and mTOR, remain 
intact (C, lane 5-8). The proteolytical YY1 
cleavage is likely to be caused by the activation of 
the Ca2+-dependent protease calpain II, that 
cleaves YY1 in other cell types (13). We carried 
out 8 hours bilirubin treatment in the presence of 
the potent membrane permeable calcium chelator 
EGTA-AM and EGTA that does not enter the 
cells. We observed that YY1 cleavage was 
diminished when the EGTA-AM was added to the 
medium (C, lane 3). The extracellular Ca2+ 
chelator EGTA, however, has little effect on 
reducing the suggested calpain II-YY1 cleavage 
(C, lane 4) (23).  
Changes in the intracellular Ca2+ content in 
response to bilirubin could activate calpain II and 
potentially account for the observed YY1 
cleavage. We measured and compared the 
intracellular Ca2+level in serum- stimulated cells 
that are cultivated in the presence of 100 µM 
bilirubin (D) for 1, and 8 hours .The data clearly 
demonstrates that 1 hours treatment with bilirubin 
results in more than 2 times Ca2+level elevation 
when compared to the control cells. The Ca2+level 
remains high 8 hours after adding bilirubin to the 
cell culture medium.  
Collectively, our data document the ability of 
bilirubin to alter the Ca2+ influx and possibly 
induce the activation of the Ca2+-calpain II circuit 
in hCASMC. We suggest that these cellular events 
ultimately manifest in the cleavage of YY1. 
 
Altered expression of RNA polymerase I, 
polymerase II, and polymerase III transcribed 
genes in response to bilirubin. We observed 
alterations in cell growth, the Raf/ERK/MAP 
kinase pathway, and the pattern of Rb 
phosphorylation, together with the reduced cellular 
YY1 content in bilirubin-treated cells. This could 
result in altered transcription of genes with cell 
cycle transition functions that are known to be 
regulated by YY1 and Rb-YY1 interaction. YY1 
participates in the regulation of all three DNA 
dependent RNA polymerases, RNA polymerase I 
(pol I), polymerase II (pol II), and polymerase III 
(pol III) (18-21). It is also known that ribosome 
biogenesis is tightly regulated during the cell cycle 
and differentiation processes [25]. We thus tested 
if cells treated with bilirubin exhibit an altered 
transcript levels of 45S rRNA and ribosomal 5S 
rRNA (Fig. 5) by RT-qPCR analysis. The 45S 
rRNA that is transcribed by pol I does not 
decrease within the initial 8 hours of treatment. 
However, a decrease is observed 16 and 24 hours 
after adding bilirubin to the growth medium. The 
pol III transcribed 5S rRNA significantly 
decreased earlier after the first 8 hours. 
Importantly, bilirubin treatment coincides with a 
time-dependent elevation in mRNA content of the 
pol II transcribed VSMC differentiation marker, 
the smooth muscle alpha actin.  
This suggests that bilirubin could arrest hVSMC 
cell growth by inhibiting the expression of pol I 
and pol III transcribed 5S rRNA and 45S rRNA.  
While the rRNAs content goes down, bilirubin has 
a positive effect on the mRNA content of the pol II 
transcribed marker of VSMC differentiation, the 
smooth muscle alpha actin, which is known to be 
repressed by YY1 (12). 
 
DISCUSSION 
 
There is considerable clinical evidence that 
elevated serum bilirubin levels are associated with 
a diminished susceptibility to atherosclerotic 
vascular disease (5-7). However, these findings do 
not necessarily implicate bilirubin as the protective 
agent at the cellular level. Since vascular smooth 
muscle cell proliferation is a key event in the 
vascular response to injury and that bilirubin is 
known to inhibit the development of 
atherosclerotic vascular disease, we examined the 
impact of bilirubin on hVSMC proliferation in 
primary human cell cultures. Treating the cells 
with bilirubin inhibited the cell proliferation in a 
dose dependent manner, while extensive 
proliferation was found in the control cells (no 
bilirubin).. In addition, while FBS-stimulated 
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 7 
control cells began to progress throughout the cell 
cycle upon serum starvation, as seen by FACS 
analysis, the bilirubin treatment retained the cells 
in the G0/G1 arrest. More importantly, the 
hVSMC response to bilirubin at the tested high 
physiological concentration does not cause 
apoptosis as shown by annexin V staining. This 
absence of apoptosis is significant given recent 
reports that apoptosis of VSMCs can trigger the 
development of neointima formation (24). 
Our data suggests that at certain concentrations 
bilirubin triggers a non toxic cascade of molecular 
events that block hVSMC proliferation.  Bilirubin 
clearly alters the phosphorylation status of Rb, a 
protein with crucial G1/S checkpoint functions 
that are essential for the cell cycle transitions (9). 
The bilirubin treatment coincides with specific 
dephosphorylation of Rb at Ser780 and Ser608 
while preserving the phospho Ser612. Such profile 
of Rb phosphorylation is likely to be essential for 
keeping the hVSMC in a growth arrested state. 
Importantly, it facilitates Rb interactions with 
specific transcription factors, including YY1 (12) 
and its cytoplasmic retention with direct 
consequences on gene transcription (12).  
One of the major cell signaling pathways known to 
alter the phosphorylation status of Rb at Ser780 
and Ser608 is the Raf/ ERK/ MAPK pathway (16). 
We observed that a significant portion of ERK-1/2 
is hypophosphorylated in bilirubin treated cells. 
Similarly, Raf and MEK are also 
hypophosphorylated, albeit to the lesser extent. It 
remains unclear how bilirubin promotes the 
accumulation of the non-phosphorylated protein 
forms. Bilirubin could, for example, inhibit Raf 
phosphorylation by inhibiting pathways upstream 
of Ras in a SMC specific manner (25). It is known 
that Ras directly interacts with and activates Raf 
by phorphorylation. Raf next phosphorylates and 
activates MEK, which in turn phosphorylates and 
activates ERKs.  Therefore, the observed low 
cellular Raf protein content and 
hypophosphorylation in response to bilirubin 
could trigger low levels of MEK and ERKs 
phosphorylation and pathway inactivation. 
Through Raf, bilirubin could also act in a cascade-
independent fashion, for example by inactivating 
transcription factor NF-kB. Such scenario could 
explain, at least in part, the lower level of 
apoptosis in bilirubin treated hVSMC. In airway 
smooth muscle cells, Taillé and colleagues 
suggested that bilirubin could also modulate the 
phosphorylation of ERK by a redox mechanism 
(17). Furthermore, bilirubin could also modulate 
other cell signaling pathways that are cross-talking 
with the ERK/MAPK pathway. The p38 pathway, 
for instance, could interact with the ERK pathway 
to alter phosphorylation of up- and downstream 
proteins. Such a hypothesis is supported by our 
previous observation that bilirubin treatment 
coincides with accumulation of 
underphosphorylated p38, a major kinase in the 
MAPK signaling pathway in mouse and rat SMCs 
(8).  
The observation that the cellular cyclin D1 protein 
content is highly reduced in response to bilirubin 
treatment is significant. Cyclin D1 is one of the 
major cellular cyclins in terms of its functional 
importance for the cell cycle transitions. Cyclin D-
Cdk4/6 complex partially phosphorylates Rb to 
trigger S phase progression (26). The observed 
low level of cyclin D1 together with the 
accumulation of underphosphorylated ERK could 
explain the appearance of hypophosphorylated Rb 
and the growth arrest in the bilirubin- treated cell  
cultures.  
The effect of bilirubin on cell signaling pathways 
is most likely a complex event including  redox- 
and other mechanisms that control the cell cycle 
status. The exact mechanism that control the low 
cellular Raf and cyclin D1 levels in response to 
bilirubin, however is important and remains to be 
determined. 
Bilirubin treatment coincides with a reduced YY1 
protein level. In this study we did not witness 
changes in YY1 mRNA levels. The lower YY1 
protein content is a result of a bilirubin-triggered 
specific YY1 proteolytic cleavage. No proteolysis 
of other Zn-finger transcription factors including 
Sp1 and mTOR could be observed. The increase in 
YY1 specific cleavage is likely to be a 
consequence of activated calcium influx and 
calpain II protease activation. Supporting evidence 
corroborating the idea that bilirubin could have an 
effect on the calcium influx, on calpain II 
activation in hVSMC, and YY1 degradation, was 
previously reported for neuronal cell cultures (22). 
Cleavage of YY1 by calpain II is likely to play 
important regulatory functions in the myogenic 
differentiation (13). The calcium influx activation 
together with the involvement of YY1 cleavage 
mechanism in the hVSMC growth arrest-response 
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to bilirubin is novel. Targeting proteases to a 
transcriptional machinery may represent a unique 
feature in the vascular gene regulation and the 
response to injury.  
Bilirubin significantly inhibited the expression of 
the pol I and pol III transcribed 45S rRNA and 5S 
rRNAs. The availability of these RNAs ultimately 
determines the ribosomal assembly and the 
cellular potential for growth and proliferation (18, 
19). As YY1 and Rb are both implicated in the 
regulation of pol I and pol III transcribed genes 
(20, 21) changes in the status of Rb 
phosphorylation together with the decreased 
protein level of YY1 most likely underlies the 
reduced 45S and 5S rRNA level of expression. It 
is possible that the bilirubin-related Rb profile of 
amino acids hypophosphorylation retains YY1 in 
the cytosol, forming Rb-YY1 complex that 
prevents YY1 migration to the nuclei and 
subsequent activation of 5S and 45S rRNA 
transcription. Such a notion is directly supported 
by our previous data showing that a direct 
correlation exists between levels of cellular 
hypophosphorylated Rb, cytosolic Rb-YY1 
content, and the hCASMC cell cycle phase (12). In 
addition, proteolytic cleavage also contributes to 
the functional nuclear YY1 deficiency, as shown 
in this study.  
Taken together, our data suggest that bilirubin 
treatment inhibits hVSMC growth through two 
mechanisms. Firstly, the impaired activation of 
Raf/ERK/MAPKs  together with the reduced 
content of cellular cyclin D1 and Raf proteins 
results in inhibited Rb phosphorylation on  serines 
608 and 780. These events impede the release of 
transcription factors that are important for VSMC 
growth, such as YY1. Secondly, there is an 
increase in specific YY1 protein cleavage as a 
result of possible bilirubin-related change in the 
calcium influx and calpain II protease activation. 
The reduced cellular protein level of the 
transcription factor YY1 itself results in a 
suppressed capacity to induce ribosomal RNA 
synthesis and cell proliferation.  
Our observations suggest that at high-normal 
levels bilirubin does not cause human VSMC cell 
death. As we have shown in this study, there are 
candidate molecules and pathways that could 
explain the association of high-normal bilirubin 
levels and the maintenance of human vascular 
homeostasis. These observations provide new 
mechanistic insights into the molecular players 
and pathways underlying the transition of hVSMC 
from proliferative to contractile phenotype and the 
response to bilirubin. They may provide 
opportunities for the development of novel 
therapeutic strategies to target vascular response to 
injury and neointimal formations.
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Figure Legends  
 
Figure 1. Effect of bilirubin treatment on hVSMC proliferation and cell cycle transition. Serum 
starved hVSMCs were cultivated in medium containing different concentrations of bilirubin and without 
bilirubin.A) [3H]-thymidine incorporation was measured for serum starved cells (lane 1), FBS stimulated 
cells (lane 2), and cells that are cultivated in medium with FBS and increasing concentrations of bilirubin, 
10 µM (lane 3), 50 µM (lane 4) and 100 µM (lane 5) as indicated bellow the bars. The [3H] content in 
cells that are cultivated in medium with FBS without bilirubin was used as reference (100%). B) Annexin 
V apoptosis assay. Cells were cultivated with 100µM bilirubin (bilirubin), without bilirubin (control), or 
with the proapoptotic mixture of TNFα (400 U) and IL-1β (100 U) as indicated below the bars. The 
number of apoptotic cells that stain positively for FITC-annexin V was determined by fluorescence 
microscopy. The total number of cells was taken as reference (100%). C) Bilirubin treatment resulted in 
cellular growth arrest at the G0/G1 phase of the cell cycle as illustrated by the FACS profile. The cell 
cycle position of serum starved cultures, and cultivated cells with bilirubin and without bilirubin, as 
indicated above the profiles, was determined by PI staining of DNA and subsequent FACS analysis. Less 
than 1 % of apoptotic cells were present in the cell cultures independently of the cell culture conditions. 
Each experiment is also illustrated by diagrams below the profiles where the bars present the quantity of 
cells in G0/G1, S, and G2 phases. Results from the experiments were obtained in triplicates. Three 
independent experiments produced consistent results. Values are mean SEM (n=3) in each group.  
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Figure 2. Bilirubin alters the Rb phosphorylation profile, YY1-Rb binding, and cellular YY1 
localization. Serum starved hVSMCs were cultivated in medium with 10% FBS and 100 µM bilirubin 
and compared for Rb phosphorylation profile and presence of YY1-Rb complexes to cells that were 
cultivated without bilirubin. A)Total cell lysates (100 µg protein) were analyzed for content of  
phosphorylated Rb at Ser780, Ser6012, and Ser608 by Western blot with specific antibodies as indicated 
above the blots: lane 1- Ser608 and Ser780 content in serum deprived cells; lane 2- Ser608 and Ser780 
content after 8 hours treatment with FBS and bilirubin (+);lane 3- 8 hours treatment with FBS alone (-); 
lane 4- 16 hours treatment with bilirubin;  lane 5- 16 hours treatment with FBS alone; lane 6-24 hours 
treatment with bilirubin(+); lane 7- 24 hours treatment minus bilirubin(-) The duration of treatment with 
FBS and bilirubin (+) and minus bilirubin (-) is shown above the lanes . The western blot results with 
anti–Rb (S612) antibody are presented as follows: lanes 1, 2, 3, 4 – lysates from cells that are FBS 
stimulated cells at different time points after stimulation as indicated above the lanes; lanes 5, 6, 7, 8-  
FBS stimulated cells together with bilirubin at different time points after stimulation. The intensity of the 
specific bands is measured in pixels as shown below the western blot panels. The bilirubin (100 µM) 
presence (+) gray or absence (-) black bar is shown at the right. Values are mean SEM of 3 independent 
experiments (P<0.05 vs. FCS-stimulated control). B) Indirect immunofluorescent staining of cells with 
rabbit anti- Rb (S612) (red) antibody and mouse anti-YY1 antibodies (green). Cells received FBS alone 
and together with bilirubin as indicated above the panels (original magnification x200, inserts original 
magnification x400).  FITC-labeled anti-mouse and Alexa595-labeled anti rabbit antibodies were used for 
visualization by fluorescent microscopy. The co-localization of both proteins results in orange staining. 
C) Cytosol extract (0.3mg) from 16 hours bilirubin-treated cells were mixed and incubated with an 
affinity matrix containing covalently attached monoclonal antibody to YY1. Captured proteins were 
analyzed by Western blot with Rb-specific antibody. Samples are as follows: inpit lysate (lane 1, IN); 
bound and eluted by boiling in 1%SDS (lane 2, B); captured with pre-immune mouse antibody (lane 3, 
C). The apparent molecular mass (indicated to the right of the panel) of Rb was estimated by comparing 
the migration to protein size markers. The migration of the hyperphosphorylated (p) and the 
hypophosphorylated (h) Rb is shown on the left. 
 
 
Figure 3. Phosphorylation and total protein levels of Raf/ERK/MAPK pathway members in 
response to bilirubin. Western blot analysis of total cell lysates from serum starved hVSMCs (lane 1); 
cells treated with(+) and without (-) bilirubin for 8 hours (lanes 2 and 3);16 hours (lanes 4 and 5); 24 
hours (lanes 6 and 7). Protein specific antibodies were used to monitor changes in protein content: total β-
actin protein content was used as a standard for equal protein loading; Raf protein content; phospho Raf; 
total MEK 1/2; phospho MEK 1/2; ERK 1/2; phospho-ERK ½; total cyclin D1. The identity of the 
specific antibodies is shown at the top of the panels.  40 µg of protein is loaded in each of the lanes. Each 
experiment is also illustrated through diagrams below the panels in which the bars present the quantity 
(pixels) of immunologically reactive protein. The molecular mass of the proteins is shown at the left of 
the panels. The bilirubin (100 µM) presence (+) or absence (-) in the cell cultures is shown above the 
lanes together with the duration (h) of treatment. Results are reproducible within 3 independent 
experiments. The bars present the average value of 3 independent experiments (P<0.05 vs. FCS-
stimulated control).  
 
Figure 4. Ca2+ influx and proteolytic cleavage of YY1 in response to bilirubin treatment. Bilirubin 
(100µM) was added to the culture medium (+) together with FBS to stimulate growth. 8h and 24 h later 
cells were harvested for mRNA and protein analyses as indicated above the lanes and bellow the bars. 
Experiments with FBS alone without bilirubin were used as a control (-). A) Total RNA and cDNA were 
prepared for RT-PCR. RT-PCR reactions were conducted with YY1 gene-specific primers as indicated 
below the bars. Reactions with β-actin primers were used as an internal control. The bars represent fold 
changes in the presence of bilirubin (P<0.04 vs. FCS-stimulated cells). B) The cellular YY1, Sp1, and 
mTOR protein content is monitored in total cell lysates by Western blot with protein-specific antibody as 
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indicated on the right of the panels. All reactions received equal amounts of protein (50µg). Lane 1, total 
cell lysate from cells after 24 hours treatment with bilirubin; lane 2, cells in the absence of bilirubin; lane 
3, cell lysate from cells that are grown in the presence of bilirubin and EGTA-AM (AM); lanes 4, cells 
are grown in the presence of bilirubin and EGTA; lane 5 and 6, Sp1-specific antibody identifies the 
presence of Sp1 protein in the lysates; lane 7 and 8, mTOR- specific antibody identifies the presence of 
total mTOR protein. The YY1, Sp1, and mTOR antibodies reactive bands are indicated on the right. The 
size markers migration is shown on the left (kDa). The results are consistent between 2 independent 
experiments. C) Cells are serum stimulated without (-) and with (+) bilirubin (100µM). One hour and 8 
hours later cells are treated with the Ca2+ indicator fura red for 20 min and the intracellular Ca2+ content is 
shown by fluorescent microscopy at 550 nm excitation. The red color corresponds to the intracellular fura 
red - Ca2+ complex.    The red color intensity in the cells is measured in pixels. Measurements are 
performed in triplicates. Three independent experiments produced consistent results (P<0.03). A 
fluorescent microscopy picture of bilirubin treated (+) and control (-) cells (8 hours) is shown bellow the 
bars.  
 
Figure 5. Effect of bilirubin on pol I, pol II, and pol III transcribed RNAs in hVSMC. Total RNA 
was isolated from bilirubin treated and untreated cell cultures and used in RT-qPCR reactions with gene-
specific primers for: pol II transcribed smooth muscle actin; 45S rRNA transcribed by pol I; 5S rRNA 
transcribed by pol III as indicated above the dyagrams. The bars represents the fold change in specific 
RNA content using the β−actin mRNA level as an endogenous reference gene that does not change in 
response to treatment. PCR reactions were conducted with total RNAs isolated from cell cultures after 0, 
8, 16, and 24 hours of bilirubin treatment as indicated below the bars. Three independent experiments 
produced consistent results (S.D. ~ ±3%). 
 
Figure 6. Model of the molecular mechanism of bilirubin induced growth arrest in hVSMC. 
Bilirubin treatment decreases cellular protein content of cyclin D1 and Raf. It also inhibits 
phosphorylation and activation of members of the Raf/ERK/MAPK pathway, resulting in the 
accumulation of hypophosphorylated at  Ser608 and Ser780 Rb that is  a key suppressor of cell cycle 
transition from G0/G1 into S phase. The hypophosphorylation profile of Rb facilitates Rb-YY1 binding, 
retention in the cytosol and consequent nuclear YY1 depletion. Bilirubin also activates intra cellular 
Ca2+influx, Ca2+-calpain protease circuit activation, and YY1 cleavage, further altering the nuclear YY1 
availability for transcription. The reduced level of nuclear YY1 results in altered mRNA content of pol I, 
pol II, and pol III transcribed genes with important functions in the VSMC cell cycle control.   
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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